The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine.

New York Attorney General Letitia James says the state will receive up to $524 million from drugmaker Teva to settle claims that the company contributed to the U.S. opioid epidemic.

Opioids maker Teva has agreed to a $4.25 billion settlement to participating states and local governments to address the opioids crisis.

European Executive Vice- President Margrethe Vestager speaks during a media conference regarding an antitrust case at EU headquarters in Brussels, Thursday, Nov. 26, 2020. The European Union has fined two pharmaceutical companies for colluding to keep a cheap alternative to a sleep disorder medicine off the market for their profit and at the expense of patients. (Johanna Geron, Pool via AP)The European Union has fined two pharmaceutical companies for colluding to keep a cheap alternative to a sleep disorder medicine off the market for their profit and at the expense of patients. Vestager said that “Teva’s and Cephalon’s pay-for-delay agreement harmed patients and national health systems, depriving them of more affordable medicines." A cheap alternative would have had a serious impact on the company, and the EU argued that Cephalon enticed Teva in 2005 to stay out of its market.